CME Medical Grand Rounds ~ The Breast Cancer Continuum: Intersecting Current and Novel Treatment Str

EVENT DETAILS AND REGISTRATION

Date:September 15, 2015

Time: 12:00 PM - 01:00 PM (PT)

Location:Conference Room B

Event Is:

  • Analyze key pathologic and molecular findings in the identification and diagnosis of early stage, locally advanced, and metastatic breast cancers
  • Determine optimal sequencing and duration for individualized treatments for patients with HER2+ metastatic breast cancer
  • Evaluate the benefits of mTOR inhibitors, non-taxane microtubules, epothilones, antibody-drug conjugates, and other agents for MBC
  • Assess the optimal use of hormonal therapy in patients with breast cancer
  • Apply current and emerging evidence supporting VEGF and other targeted therapy in breast cancer treatment
  • Utilize prognostic assays in determining treatments for patients with breast cancer
  • Incorporate current treatment guidelines into decision making for treating patients with breast cancer

Presenters:Rowan Chlebowski, MD, PhD

ADDITIONAL DETAILS:

Objectives:

  • Analyze key pathologic and molecular findings in the identification and diagnosis of early stage, locally advanced, and metastatic breast cancers
  • Determine optimal sequencing and duration for individualized treatments for patients with HER2+ metastatic breast cancer
  • Evaluate the benefits of mTOR inhibitors, non-taxane microtubules, epothilones, antibody-drug conjugates, and other agents for MBC
  • Assess the optimal use of hormonal therapy in patients with breast cancer
  • Apply current and emerging evidence supporting VEGF and other targeted therapy in breast cancer treatment
  • Utilize prognostic assays in determining treatments for patients with breast cancer
  • Incorporate current treatment guidelines into decision making for treating patients with breast cancer

Who should attend:

This activity is intended for medical oncologists, surgeons, radiation oncologists, researchers, oncology nurses, and other healthcare providers involved in the treatment and management of breast cancer.

Sponsor(s):Educational Grant from Genentech, Inc.

CME credits:1.0 AMA/PRA Category 1 Credit™ The City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. City of Hope designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.TM

R.S.V.P.: First Come First Serve

Contact:

CME Department